Commentary on research of bone morphogenetic protein discussed in review article: Genetic advances in the regeneration of the intervertebral disc

Nancy E. Epstein

Department of Neurosurgery, The Albert Einstein College of Medicine, Bronx, New York, 10461, and Chief of Neurosurgical Spine/Education, Department of Neuroscience, Winthrop University Hospital, Mineola, NY 11501

E-mail: *Nancy E. Epstein - nancy.epsteinmd@gmail.com
*Corresponding author

Received: 01 January 13  Accepted: 03 January 13  Published: 22 March 13

Abstract

Background: In Maerz, Herkowitz and Baker’s review, Molecular and Genetic Advances in the Regeneration of the Intervertebral Disc, they also included an assessment of both in vivo and in vitro complications attributed to Bone Morphogenetic Protein (BMP): BMP-2, BMP-7. This topic is of particular interest to spinal surgeons, as INFUSE/BMP (Medtronic, Memphis, TN, USA) is utilized, mostly off-label in the cervical, thoracic, and lumbar spine, where it has been associated with significant perioperative and postoperative complications.

Methods: BMP-2 and BMP-7 are the only human recombinant growth factors approved by the Food and Drug Administration (FDA) for anterior lumbar interbody fusion (ALIF) in combination with the Lumbar Tapered Fusion Device (LT Cage: Medtronic, Memphis, TN, USA). BMP, however, is more typically utilized “off-label” in many other areas of the spine, where it has been associated with numerous complications.

Results: Maerz, et al. documented multiple in vivo and in vitro laboratory-based animal studies dating back to the early 2000’s in which BMP (INFUSE is the clinically available product: Medtronic, Memphis, TN) contributed to multiple complications, especially when utilized at higher doses. These complications included; inflammation/inflammatory processes, increased vascularity, fibroblastic proliferation, and catabolism.

Conclusion: Maerz, et al. reviewed the increased risks associated with utilizing high dose BMP=INFUSE in spinal surgery, particularly when utilized “off-label”. The authors clearly indicate that BMP/INFUSE should be further investigated (based on the old and new findings) to better determine/confirm its safety, efficacy, and dosing.

Key Words: Animal laboratory studies, bone morphogenetic protein, clinical, infuse, intervertebral disc, regeneration, spinal surgery

INTRODUCTION

Maerz, Herkowitz, and Baker have written an excellent review article, Molecular and Genetic Advances in the Regeneration of the Intervertebral Disc.[1] Of critical interest to the practicing spinal surgeon was their
presentation of laboratory-documented (in vivo and in vitro studies) complications attributed to INFUSE/Bone Morphogenetic Protein (BMP) (Medtronic, Memphis, TN, USA), some dating back to the mid 2000s. More spinal surgeons who predominantly use this product “off-label” have been experiencing more INFUSE/BMP-related complications following spinal fusions. According to Maerz, et al. review of the literature, many of these complications were known in the early-mid 2000’s.

**FOOD AND DRUG ADMINISTRATION “ON-LABEL” VS. “OFF-LABEL” USE OF BONE MORPHOGENETIC PROTEIN**

Maerz, et al. noted that BMP-2 and BMP-7 (OP-1) are the only human recombinant growth factors (osteoinductive properties) approved by the Food and Drug Administration (FDA). It is, however, rarely used for the FDA approved anterior lumbar interbody fusion (ALIF) in combination with the Lumbar Tapered Fusion Device (LT Cage) (Medtronic, Memphis, TN, USA). It is more typically utilized in an off-label capacity in other areas of the spine, where high dose application is increasingly associated with a myriad of complications. Watts’ noted the tragic, unregulated, and uncontained, “no holds barred”, “off-label” use of INFUSE/BMP particularly in the anterior cervical spine, and attributed this to a failure in neurosurgical and orthopedic leadership.

**IN VITRO, BMP-2 PROMOTES EXPRESSION OF CHONDROGENIC, NOT OSTEOGENIC PHENOTYPES OF HUMAN INTERVERTEBRAL DISC CELLS**

BMP-2, in vitro, upregulates multiple genes and enhances the expression of many proteins. In 2003, Kim, et al. observed how BMP-2 promotes the expression of “chondrogenic, not osteogenic, phenotypes of human intervertebral disc cells,” resulting in greater proteoglycan synthesis, the up-regulation of articular chondrocytes, and intervertebral disc cells (IVD). Furthermore, different concentrations of rhBMP-2 were utilized, “without inducing an osteogenic phenotype and/or associated calcifications or mineralizations.” They concluded that rhBMP-2 might effectively be utilized to regenerate the matrix of the IVD.

**IN VITRO, BMP-2 IS UNTHERAPEUTIC, AND INDUCES APOPTOSIS**

In 2011, McCanless, et al. evaluated the in vitro impact of BMP-2 on cell proliferation/extracellular matrix (ECM) synthesis of the nucleus pulposus (NP)-like differentiated mesenchymal stem cells (MSCs). They found that “BMP-2 induced apoptosis, Collagen 1 (Col I) accumulation, and aggrecan production hindrance, furthermore, they found it was untherapeutic.”

**IN VIVO, BMP-2 PROMOTED DEGENERATIVE DISC CHANGES AND OTHER COMPLICATIONS**

In an in vivo animal model in 2011, Huang, et al. showed that rhBMP-2 promoted more degenerative changes in the disc vs. controls, while also resulting in other complications; “increased inflammation, vascularity, and fibroblastic proliferation in rhBMP-2-treated animals compared with saline-treated animals.”

**IN VITRO BMP-14, AT HIGHER DOSES, PRODUCED MORE COMPLICATIONS**

In 2004, Wang, et al. noted that the in vitro applications of BMP-14 (GDF-5) induced cellular activation/proliferation in primary IVD cells, promoting collagen synthesis. Higher doses produced inflammatory reactions in the adjacent vertebrae and connective tissue that infiltrated the nucleus. This indicated that “the positive effect of GDF-5 may depend on dosing, and that multiple treatments can cause catabolic and/or inflammatory processes.”

**INSULIN-LIKE GROWTH FACTOR-1 PROMOTED COMPLICATIONS AT HIGHER DOSES**

In 2004, Walsh, et al. further demonstrated that one injection of insulin-like growth factor-1 (IGF-1) into a degenerate murine disc resulted in increased cell density and proliferation at 1 week, while multiple injections resulted in inflammatory reactions in adjacent vertebrae, indicating a dose-dependent response.

**CONCLUSION**

In their review article, Maerz, et al. discussed how BMP/INFUSE, particularly when applied at higher dosages in vitro and in vivo models, resulted in multiple adverse reactions. Complications included apoptosis of intervertebral disc cells, inflammatory reactions, increased vascularity, fibroblast infiltration, and other catabolic effects. Of interest, some of the reviewed studies were published in the early 2000s, while others are more recent. The data highlighted by Maerz, et al. indicate that perhaps spine surgeons should reconsider the use of BMP/INFUSE “off-label” to perform spinal fusions. The basic scientists should assist spinal surgeons in the reassessment of BMP/INFUSE, particularly when it comes to assessing its safety, efficacy, and appropriate dosing levels.
REFERENCES

1. Huang B, Zhuang Y, Li CQ, Liu LT, Zhou Y. Regeneration of the intervertebral disc with nucleus pulposus cell-seeded collagen II/hyaluronan/chondroitin-6-sulfate tri-copolymer constructs in a rabbit disc degeneration model. Spine (Phila Pa 1976) 2011;36:2252-9.

2. Kim DJ, Moon SH, Kim H, Kwon UH, Park MS, Han KJ, et al. Bone morphogenetic protein-2 facilitates expression of chondrogenic, not osteogenic, phenotype of human intervertebral disc cells. Spine (Phila Pa 1976) 2003;28:2679-84.

3. Maerz T, Harry Herkowitz H, Kevin Baker K. Review article: Molecular and genetic advances in the regeneration of the intervertebral disc. Surgical Neurology International: Spine Supplement 2013. [In press]

4. McCanless JD, Cole JA, Slack SM, Bumgardner JD, Zamora PO, Haggard WO. Modeling nucleus pulposus regeneration in vitro: Mesenchymal stem cells, alginate beads, hypoxia, bone morphogenetic protein-2, and synthetic peptide B2A. Spine (Phila Pa 1976) 2011;36:2275-85.

5. Walsh AJ, Bradford DS, Lotz JC. In vivo growth factor treatment of degenerated intervertebral discs. Spine (Phila Pa 1976) 2004;29:156-63.

6. Wang H, Kroeker M, Hanke M, Ries R, Schmid C, Poller W, et al. Release of active and depot GDF-5 after adenovirus-mediated overexpression stimulates rabbit and human intervertebral disc cells. J Mol Med (Berl) 2004;82:126-34.

7. Watts C. Off-label use of rhBMP-2. Surg Neurol Int 2011;2:4.